{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T23:58:29Z","timestamp":1766102309604,"version":"3.37.3"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"FI1","license":[{"start":{"date-parts":[[2020,1,31]],"date-time":"2020-01-31T00:00:00Z","timestamp":1580428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"The BMS"},{"name":"Pfizer European Thrombosis Investigator Initiated Research Program","award":["CV185-697"],"award-info":[{"award-number":["CV185-697"]}]},{"DOI":"10.13039\/501100007290","name":"Obel Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007290","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>To describe the risks of thromboembolism and major bleeding complications in anticoagulated patients with atrial fibrillation (AF) and native aortic or mitral valvular heart disease using data reflecting clinical practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Descriptive cohort study of anticoagulated patients with incident AF and native aortic or mitral valvular heart disease, identified in nationwide Danish registries from 2000 to 2018. A total of 10\u00a0043 patients were included, of which 5190 (51.7%) patients had aortic stenosis, 1788 (17.8%) patients had aortic regurgitation, 327 (3.3%) patients had mitral stenosis, and 2738 (27.3%) patients had mitral regurgitation. At 1\u2009year after AF diagnosis, the risk of thromboembolism was 4.6% in patients with mitral stenosis taking a vitamin K antagonist (VKA), and 2.6% in patients with aortic stenosis taking a VKA or non-vitamin K antagonist oral anticoagulant (NOAC). For patients with aortic or mitral regurgitation, the risks of thromboembolism ranged between 1.5%-1.8% in both treatment groups. For the endpoint of major bleeding, the risk was \u223c5.5% in patients with aortic stenosis or mitral stenosis treated with a VKA, and 3.3\u20134.0% in patients with aortic or mitral regurgitation. For patients treated with a NOAC, the risk of major bleeding was 3.7% in patients with aortic stenosis and \u223c2.5% in patients with aortic or mitral regurgitation.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>When using data reflecting contemporary clinical practice, our observations suggested that 1 year after a diagnosis of AF, anticoagulated patients with aortic or mitral valvular heart disease had dissimilar risk of thromboembolism and major bleeding complications. Specifically, patients with aortic stenosis or mitral stenosis were high-risk subgroups. This observation may guide clinicians regarding intensity of clinical follow-up.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvaa008","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T12:10:46Z","timestamp":1579867846000},"page":"f101-f110","source":"Crossref","is-referenced-by-count":16,"title":["Thromboembolism and bleeding complications in anticoagulated patients with atrial fibrillation and native aortic or mitral valvular heart disease: a descriptive nationwide cohort study"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3538-7968","authenticated-orcid":false,"given":"Line","family":"Melgaard","sequence":"first","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thure Filskov","family":"Overvad","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"},{"name":"Department of Medicine, North Denmark Regional Hospital, Hjoerring, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Jensen","sequence":"additional","affiliation":[{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory Y H","family":"Lip","sequence":"additional","affiliation":[{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"},{"name":"Liverpool Centre for Cardiovascular Sciences, University Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torben Bjerregaard","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2922-6970","authenticated-orcid":false,"given":"Peter Br\u00f8nnum","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark"},{"name":"Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Faculty of Health, Aalborg University, Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2020,1,31]]},"reference":[{"key":"2021040921531445200_pvaa008-B1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/eut263","article-title":"Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events\u2014European Registry in Atrial Fibrillation (PREFER in AF)","volume":"16","author":"Kirchhof","year":"2014","journal-title":"Europace"},{"key":"2021040921531445200_pvaa008-B2","first-page":"22","article-title":"A clinical evaluation of atrial fibrillation in rheumatic heart disease","volume":"63","author":"Sharma","year":"2015","journal-title":"J Assoc Physicians India"},{"key":"2021040921531445200_pvaa008-B3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0002-9149(97)89145-X","article-title":"Prevalence and predictors of atrial fibrillation in rheumatic valvular heart disease","volume":"77","author":"Diker","year":"1996","journal-title":"Am J Cardiol"},{"key":"2021040921531445200_pvaa008-B4","first-page":"1","article-title":"Subtypes of atrial fibrillation with concomitant valvular heart disease derived from electronic health records: phenotypes, population prevalence, trends and prognosis","volume":"220","author":"Banerjee","year":"2019","journal-title":"Europace"},{"key":"2021040921531445200_pvaa008-B5","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ijcard.2018.03.017","article-title":"Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification","volume":"260","author":"Bisson","year":"2018","journal-title":"Int J Cardiol"},{"key":"2021040921531445200_pvaa008-B6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1093\/eurheartj\/ehv163","article-title":"Prognostic value of CHA2DS2-VASc score in patients with \u201cnon-valvular atrial fibrillation\u201d and valvular heart disease: the Loire Valley Atrial Fibrillation Project","volume":"36","author":"Philippart","year":"2015","journal-title":"Eur Heart J"},{"key":"2021040921531445200_pvaa008-B7","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1136\/heartjnl-2015-308120","article-title":"Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban","volume":"102","author":"Breithardt","year":"2016","journal-title":"Heart"},{"key":"2021040921531445200_pvaa008-B8","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2021040921531445200_pvaa008-B9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"2021040921531445200_pvaa008-B10","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"2021040921531445200_pvaa008-B11","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"2021040921531445200_pvaa008-B12","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1161\/CIRCULATIONAHA.115.020950","article-title":"Comparison of dabigatran and warfarin in patients with atrial fibrillation and valvular heart disease: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy)","volume":"134","author":"Ezekowitz","year":"2016","journal-title":"Circulation"},{"key":"2021040921531445200_pvaa008-B13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1177\/1403494810387965","article-title":"The Danish Civil Registration System","volume":"39","author":"Pedersen","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021040921531445200_pvaa008-B14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021040921531445200_pvaa008-B15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/1403494811401482","article-title":"The Danish National Patient Register","volume":"39","author":"Lynge","year":"2011","journal-title":"Scand J Public Health"},{"key":"2021040921531445200_pvaa008-B16","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/1403494817716582","article-title":"Predictive value of stroke discharge diagnoses in the Danish National Patient Register","volume":"45","author":"L\u00fchdorf","year":"2017","journal-title":"Scand J Public Health"},{"key":"2021040921531445200_pvaa008-B17","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"key":"2021040921531445200_pvaa008-B18","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1001\/jamacardio.2018.3152","article-title":"Outcomes of patients with asymptomatic aortic stenosis followed up in heart valve clinics","volume":"3","author":"Lancellotti","year":"2018","journal-title":"JAMA Cardiol"},{"key":"2021040921531445200_pvaa008-B19","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1016\/j.jacc.2015.10.001","article-title":"Initial surgical versus conservative strategies in patients with asymptomatic severe aortic stenosis","volume":"66","author":"Taniguchi","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531445200_pvaa008-B20","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.jacc.2019.08.004","article-title":"Poor long-term survival in patients with moderate aortic stenosis","volume":"74","author":"Strange","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531445200_pvaa008-B21","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/europace\/euv288","article-title":"Non-vitamin K antagonist oral anticoagulants in atrial fibrillation accompanying mitral stenosis: the concept for a trial","volume":"18","author":"Caterina","year":"2016","journal-title":"Europace"},{"key":"2021040921531445200_pvaa008-B22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1212\/WNL.28.10.973","article-title":"Epidemiologic assessment of chronic atrial fibrillation and risk of stroke: the framingham Study","volume":"28","author":"Wolf","year":"1978","journal-title":"Neurology"},{"key":"2021040921531445200_pvaa008-B23","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jstrokecerebrovasdis.2012.08.001","article-title":"Free floating left atrial ball thrombus: a rare cause of stroke","volume":"22","author":"Rider","year":"2013","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2021040921531445200_pvaa008-B24","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1136\/hrt.24.3.349","article-title":"The natural history of 271 patients with mitral stenosis under medical treatment","volume":"24","author":"Olesen","year":"1962","journal-title":"Br Hear J"},{"key":"2021040921531445200_pvaa008-B25","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s10554-013-0299-2","article-title":"Massive left atrium thrombus","volume":"30","author":"Santos","year":"2014","journal-title":"Int J Cardiovasc Imaging"},{"key":"2021040921531445200_pvaa008-B26","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2018.12.047","article-title":"Outcomes of direct oral anticoagulants in patients with mitral stenosis","volume":"73","author":"Kim","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2021040921531445200_pvaa008-B27","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","article-title":"2017 ESC\/EACTS Guidelines for the management of valvular heart disease","volume":"38","author":"Baumgartner","year":"2017","journal-title":"Eur Heart J"},{"key":"2021040921531445200_pvaa008-B28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIR.0000000000000503","article-title":"2017 AHA\/ACC focused update of the 2014 AHA\/ACC Guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"135","author":"Nishimura","year":"2017","journal-title":"Circulation"},{"key":"2021040921531445200_pvaa008-B29"},{"key":"2021040921531445200_pvaa008-B30","doi-asserted-by":"crossref","first-page":"3328","DOI":"10.1093\/eurheartj\/ehu352","article-title":"What is \u201cvalvular\u201d atrial fibrillation? A reappraisal","volume":"35","author":"De Caterina","year":"2014","journal-title":"Eur Heart J"},{"key":"2021040921531445200_pvaa008-B31","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/heartjnl-2017-312758","article-title":"Current recommendations for anticoagulant therapy in patients with valvular heart disease and atrial fibrillation: the ACC\/AHA and ESC\/EACTS Guidelines in Harmony \u2026 but not Lockstep!","volume":"104","author":"Erwin","year":"2018","journal-title":"Heart"},{"key":"2021040921531445200_pvaa008-B32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/CIRCEP.118.006990","article-title":"Stroke and thromboembolism in patients with atrial fibrillation and mitral regurgitation","volume":"12","author":"Bisson","year":"2019","journal-title":"Circ Arrhythmia Electrophysiol"},{"key":"2021040921531445200_pvaa008-B33","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archinte.167.3.239","article-title":"Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V","volume":"167","author":"White","year":"2007","journal-title":"Arch Intern Med"},{"key":"2021040921531445200_pvaa008-B34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/1471-2288-11-83","article-title":"The predictive value of ICD-10 diagnostic coding used to assess Charlson comorbidity index conditions in the population-based Danish National Registry of Patients","volume":"11","author":"Thygesen","year":"2011","journal-title":"BMC Med Res Methodol"},{"key":"2021040921531445200_pvaa008-B35","doi-asserted-by":"crossref","first-page":"149","DOI":"10.3109\/14017431.2012.673728","article-title":"Validity of the diagnoses atrial fibrillation and atrial flutter in a Danish patient registry","volume":"46","author":"Rix","year":"2012","journal-title":"Scand Cardiovasc J"},{"key":"2021040921531445200_pvaa008-B36","doi-asserted-by":"crossref","first-page":"e012832","DOI":"10.1136\/bmjopen-2016-012832","article-title":"Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study","volume":"6","author":"Sundb\u00f8ll","year":"2016","journal-title":"BMJ Open"},{"key":"2021040921531445200_pvaa008-B37","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLoS One"},{"key":"2021040921531445200_pvaa008-B38","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1159\/000102143","article-title":"Validity of stroke diagnoses in a National Register of Patients","volume":"28","author":"Krarup","year":"2007","journal-title":"Neuroepidemiology"},{"key":"2021040921531445200_pvaa008-B39","doi-asserted-by":"crossref","first-page":"941","DOI":"10.2147\/CLEP.S167576","article-title":"Intracerebral hemorrhage: positive predictive value of diagnosis codes in two nationwide danish registries","volume":"10","author":"Hald","year":"2018","journal-title":"Clin Epidemiol"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvaa008\/32517675\/pvaa008.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/FI1\/f101\/37011074\/pvaa008.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ehjcvp\/article-pdf\/7\/FI1\/f101\/37011074\/pvaa008.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T21:56:37Z","timestamp":1618005397000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/7\/FI1\/f101\/5719029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,31]]},"references-count":39,"journal-issue":{"issue":"FI1","published-online":{"date-parts":[[2020,1,31]]},"published-print":{"date-parts":[[2021,4,9]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvaa008","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"type":"print","value":"2055-6837"},{"type":"electronic","value":"2055-6845"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,1,31]]}}}